Alder BioPharma (ALDR) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Starts Alder Biopharm (ALDR) at Overweight
October 31, 2016 6:13 AM EDTPiper Jaffray initiates coverage on Alder Biopharm (NASDAQ: ALDR) with a Overweight rating and a price target of $47.00.
Analyst Charles Duncan commented, "We are initiating coverage on Alder with an OW rating and $47 PT based on risk-adjusted value of its anti-CGRP candidate ALD403... More
